NCT01985555View on ClinicalTrials.gov

Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Tumors
Interventions
DRUG

Volitinib(HMPL-504)

Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.

Trial Locations (1)

Unknown

BeijingCancer Hospital, Beijing

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT01985555 - Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter